Literature DB >> 6737018

Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience.

E M Rosen, J R Cassady, C N Frantz, C Kretschmar, R Levey, S E Sallan.   

Abstract

The treatment results for 118 patients with neuroblastoma seen at the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital from 1970 to 1980 were analyzed. Patients were treated with a combination of surgery, radiation therapy, and chemotherapy depending on stage and age. Disease-free survival was excellent in all patient groups except those over one year of age with stage IV disease, a group for which currently available therapy cures only a small proportion of patients. Patients with stage III disease and older patients with stage II disease did extremely well (survival of 81% and 89%, respectively) and may have benefited from intensive treatment with all three modalities. Survival for infants (under one year) with stage IV neuroblastoma (90%) has clearly improved with intensive combination chemotherapy. With combination approaches and newer, more effective systemic regimens, a real impact on survival appears to have been made in the last decade. Better approaches will be necessary to cure more than an occasional older patient with stage IV disease.

Entities:  

Mesh:

Year:  1984        PMID: 6737018     DOI: 10.1200/JCO.1984.2.7.719

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.

Authors:  Brian H Kushner; Nai-Kong V Cheung; Christopher A Barker; Kim Kramer; Shakeel Modak; Karima Yataghene; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-08       Impact factor: 7.038

2.  Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.

Authors:  Jared R Robbins; Matthew J Krasin; Atmaram S Pai Panandiker; Amy Watkins; Jianrong Wu; Victor M Santana; Wayne L Furman; Andrew M Davidoff; Lisa M McGregor
Journal:  J Pediatr Surg       Date:  2010-04       Impact factor: 2.545

3.  Expression of mdr-1/P-glycoprotein in human neuroblastoma.

Authors:  S E Bates; C Y Shieh; M Tsokos
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

4.  Primary cerebral neuroblastoma (neurocytoma) in adults.

Authors:  E Ferreol; R Sawaya; G M de Courten-Myers
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

5.  Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement.

Authors:  Matthew J Ferris; Hasan Danish; Jeffrey M Switchenko; Claudia Deng; Bradley A George; Kelly C Goldsmith; Karen J Wasilewski; W Thomas Cash; Mohammad K Khan; Bree R Eaton; Natia Esiashvili
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-27       Impact factor: 7.038

6.  Adrenal tumours in Chinese.

Authors:  K Y Lam
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  Cisplatin and cranial irradiation-related hearing loss in children.

Authors:  Rajasekharan Warrier; Aman Chauhan; Murali Davluri; Sonya L Tedesco; Joseph Nadell; Randall Craver
Journal:  Ochsner J       Date:  2012

8.  Intraoperative radiation therapy for advanced neuroblastoma: the problem of securing the IORT field.

Authors:  Kiminobu Sugito; Takeshi Kusafuka; Mayumi Hoshino; Mikiya Inoue; Hiroshi Goto; Taro Ikeda; Noritsugu Hagiwara; Tsugumichi Koshinaga; Masahiro Fukuzawa; Masanori Nakamura; Hiroyuki Shichino; Motoaki Chin; Hideo Mugishima; Tsutomu Saito; Yoshiaki Tanaka
Journal:  Pediatr Surg Int       Date:  2007-10-30       Impact factor: 1.827

9.  Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study.

Authors:  Kevin X Liu; Arlene Naranjo; Fan F Zhang; Steven G DuBois; Steve E Braunstein; Stephan D Voss; Geetika Khanna; Wendy B London; John J Doski; James D Geiger; Susan G Kreissman; Stephan A Grupp; Lisa R Diller; Julie R Park; Daphne A Haas-Kogan
Journal:  J Clin Oncol       Date:  2020-06-12       Impact factor: 44.544

10.  Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?

Authors:  John T Lucas; M Beth McCarville; David A Cooper; Mikhail Doubrovin; Daniel Wakefield; Teresa Santiago; Yimei Li; Xingyu Li; Matthew Krasin; Victor Santana; Wayne Furman; Andrew M Davidoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.